References
- ACD. (2010). PhysChem History, v12.0. Toronto, ON, Canada: Advanced Chemical Development, Inc
- Baer BR, Rettie AE, Henne KR. (2005). Bioactivation of 4-Ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem Res Toxicol 18:855–64
- Barter ZE, Bayliss MK, Beaune PH, et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33–45
- Boase S, Miners JO. (2005). In vitroin vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493–503
- Bowalgaha K, Elliot DJ, Mackenzie PI, et al. (2005). S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423–33
- Boye SL, Kerdpin O, Elliot DJ, et al. (2004). Optimizing bacterial expression of catalytically active human cytochromes P450: comparison of CYP2C8 and CYP2C9. Xenobiotica 34:49–60
- Bramer SL, Suri A. (1999). Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. Clin Pharmacokinet 37:41–51
- Cuttle L, Munns AJ, Hogg NA, et al. (2000). Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos 28:945–50
- Druckova A, Marnett LJ. (2006). Characterization of the amino acid adducts of the enedial derivative of teucrin A. Chem Res Toxicol 19:1330–40
- Druckova A, Mernaugh RL, Ham AJL, Marnett LJ. (2007). Identification of the protein targets of the reactive metabolite of teucrin A in vivo in the rat. Chem Res Toxicol 20:1393–408
- EMA. (2012). In: Committee for Human Medicinal Products, ed. Guideline on the investigation of drug interactions. London, UK: European Medicines Agency
- Fisher MB, Campanale K, Ackermann BL, et al. (2000). In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560–6
- FDA. (2008). In: Center for Drug Evaluation and Research, ed. Guidance for industry: safety testing of drug metabolites. Rockville (MD): Food and Drug Administration
- Gill KL, Houston JB, Galetin A. (2012). Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos 40:825–35
- Ha-Duong NT, Dijols S, Macherey AC, et al. (2001). Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40:12112–22
- Hallifax D, Houston JB. (2006). Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab Dispos 34:1829–36
- Harper TW, Brassil PJ. (2008). Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10:200–7
- Hosokawa M. (2008). Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13:412
- Jamei M, Marciniak S, Edwards D, et al. (2013). The SimCYP population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol 1:14
- Kumar GN, Surapaneni S. (2001). Role of drug metabolism in drug discovery and development. Med Res Rev 21:397–411
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193:265–75
- Masimirembwa CM, Bredberg U, Andersson TB. (2003). Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin Pharmacokinet 42:515–28
- Meng Q, Liu K. (2014). Pharmacokinetic interactions between herbal medicines and prescribed drugs: focus on drug metabolic enzymes and transporters. Curr Drug Metab 15:791–807
- Miners JO, Bowalgaha K, Elliot DJ, et al. (2011). Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos 39:644–52
- Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug–drug interaction potential. Drug Metab Rev 42:196–208
- Miners JO, Veronese ME, Birkett DJ. (1994). Chapter 31. In vitro approaches for the prediction of human drug metabolism. Annu Rep Med Chem 29:307–16
- Miners JO, Veronese ME, Birkett DJ. (1996). Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods Enzymol 272:139–45
- Parikh A, Gillam EM, Guengerich FP. (1997). Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat Biotechnol 15:784–8
- Peterson LA. (2012). Reactive metabolites in the biotransformation of molecules containing a furan ring. Chem Res Toxicol 26:6–25
- Polasek TM, Elliot DJ, Somogyi AA, et al. (2006). An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol 61:570–84
- Romberg RW, Lee L. (1995). Comparison of the hydrolysis rates of morphine-3-glucuronide and morphine-6-glucuronide with acid and beta-glucuronidase. J Anal Toxicol 19:157–62
- Roth BL, Baner K, Westkaemper R, et al. (2002). Salvinorin A: a potent naturally occurring nonnitrogenous κ opioid selective agonist. Proc Natl Acad Sci U S A 99:11934–9
- Rowland A, Gaganis P, Elliot DJ, et al. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro–in vivo extrapolation. J Pharmacol Exp Ther 321:137–47
- Rowland A, Knights KM, Mackenzie PI, Miners JO. (2008). The “albumin effect” and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056–62
- Salinas-Sánchez DO, Zamilpa A, Pérez S, et al. (2015). Effect of hautriwaic acid isolated from Dodonaea viscosa in a model of Kaolin/Carrageenan-induced monoarthritis. Planta Med 81:1240–7
- Sanghani SP, Sanghani PC, Schiel MA, Bosron WF. (2009). Human carboxylesterases: an update on CES1, CES2 and CES3. Protein Pept Lett 16:1207–14
- Schmidt MS, Prisinzano TE, Tidgewell K, et al. (2005). Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. J Chromatogr B Analyt Technol Biomed Life Sci 818:221–5
- Sheffler DJ, Roth BL. (2003). Salvinorin A: the ‘magic mint' hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107–9
- Shipkova M, Schütz E, Armstrong VW, et al. (2000). Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46:365–72
- Simpson BS, Claudie DJ, Gerber JP, et al. (2011). In vivo activity of benzoyl ester clerodane diterpenoid derivatives from Dodonaea polyandra. J Nat Prod 74:650–7
- Simpson BS, Claudie DJ, Smith NM, et al. (2010). Evaluation of the anti-inflammatory properties of Dodonaea polyandra, a Kaanju traditional medicine. J Ethnopharmacol 132:340–3
- Simpson BS, Luo X, Costabile M, et al. (2014). Polyandric acid A, a clerodane diterpenoid from the Australian medicinal plant Dodonaea polyandra, attenuates pro-inflammatory cytokine secretion in vitro and in vivo. J Nat Prod 77:85–91
- Simpson BS, Luo X, Wang J, et al. (2015). Development and evaluation of a topical anti-inflammatory preparation containing Dodonaea polyandra extract. J Pharm Pharm Sci 18:578–99
- Sykes MJ, Sorich MJ, Miners JO. (2006). Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes. J Chem Inf Model 46:2661–73
- Tassaneeyakul W, Birkett DJ, Veronese ME, et al. (1994). Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 4:281–4
- Teksin ZS, Lee IJ, Nemieboka NN, et al. (2009). Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 72:471–7
- Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006a). Selectivity of substrate (trifluroperazine) and inhibitor (amytriptiline, androsterone, canreonic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “probes” for human UDP-glucuronosyltransferases. Drug Metab Dispos 34:449–56
- Uchaipichat V, Mackenzie PI, Guo XH, et al. (2004). Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-napthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos 32:413–23
- Uchaipichat V, Winner LK, Mackenzie PI, et al. (2006b). Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 61:427–39
- VandenBrink BM, Foti RS, Rock DA, et al. (2011). Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546–54
- Walsky RL, Obach RS, Hyland R, et al. (2012). Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686–97